Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells.

[1]  C. Ren,et al.  Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases , 2022, Immunologic Research.

[2]  T. Hu,et al.  Recent progress in TGF-β inhibitors for cancer therapy. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  H. Koga,et al.  Promotion of liver regeneration and anti‑fibrotic effects of the TGF‑β receptor kinase inhibitor galunisertib in CCl4‑treated mice. , 2020, International journal of molecular medicine.

[4]  Zoe Boyer-Diaz,et al.  Animal Models for Liver Disease - A Practical Approach for Translational Research. , 2020, Journal of hepatology.

[5]  J. Tabernero,et al.  Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer , 2018, British Journal of Cancer.

[6]  M. Patterson,et al.  Miglustat in Niemann-Pick disease type C patients: a review , 2018, Orphanet Journal of Rare Diseases.

[7]  E. Tapper,et al.  Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study , 2018, British Medical Journal.

[8]  Z. Duan,et al.  Glucosylceramide synthase regulates the proliferation and apoptosis of liver cells in vitro by Bcl-2/Bax pathway , 2017, Molecular medicine reports.

[9]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[10]  Ruchi Bansal,et al.  Clinical Advancements in the Targeted Therapies against Liver Fibrosis , 2016, Mediators of inflammation.

[11]  A. Hata,et al.  TGF-β Signaling from Receptors to Smads. , 2016, Cold Spring Harbor perspectives in biology.

[12]  B. Runyon,et al.  Treatment of Patients with Cirrhosis. , 2016, The New England journal of medicine.

[13]  G. Elpek.  Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. , 2014, World journal of gastroenterology.

[14]  C. Feghali-Bostwick,et al.  Fibroblasts in fibrosis: novel roles and mediators , 2014, Front. Pharmacol..

[15]  Emmanuel A Tsochatzis,et al.  Liver cirrhosis , 2014, The Lancet.

[16]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[17]  J. Ladero.  Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis C , 2011, Hepatitis monthly.

[18]  T. Kolter.  A view on sphingolipids and disease. , 2011, Chemistry and physics of lipids.

[19]  Yu Wakabayashi,et al.  Cellular and molecular basis for the regulation of inflammation by TGF-beta. , 2010, Journal of biochemistry.

[20]  C. Ficicioglu.  Review of miglustat for clinical management in Gaucher disease type 1 , 2008, Therapeutics and clinical risk management.

[21]  T. Wynn,et al.  Cellular and molecular mechanisms of fibrosis , 2008, The Journal of pathology.

[22]  S. Milstien,et al.  Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. , 2006, Biochimica et biophysica acta.

[23]  J. Fallowfield,et al.  Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. , 2004, Gastroenterology.

[24]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[25]  L. Weber,et al.  Hepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model , 2003, Critical reviews in toxicology.

[26]  John P. Iredale,et al.  Inhibition of Apoptosis of Activated Hepatic Stellate Cells by Tissue Inhibitor of Metalloproteinase-1 Is Mediated via Effects on Matrix Metalloproteinase Inhibition , 2002, The Journal of Biological Chemistry.

[27]  J. Ohanian,et al.  Sphingolipids in mammalian cell signalling , 2001, Cellular and Molecular Life Sciences CMLS.

[28]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[29]  J. Iredale,et al.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. , 1998, The Journal of clinical investigation.

[30]  C. López-Otín,et al.  Differential Effects of Transforming Growth Factor-β on the Expression of Collagenase-1 and Collagenase-3 in Human Fibroblasts* , 1998, The Journal of Biological Chemistry.

[31]  V. Kaartinen,et al.  Abnormal lung development and cleft palate in mice lacking TGF–β3 indicates defects of epithelial–mesenchymal interaction , 1995, Nature Genetics.

[32]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[33]  R. Schwabe,et al.  Mouse Models of Liver Fibrosis. , 2021, Methods in molecular biology.

[34]  Liying Li,et al.  GASTROINTESTINAL, HEPATOBILIARY, AND PANCREATIC PATHOLOGY Intracellular Sphingosine 1-Phosphate Contributes to Collagen Expression of Hepatic Myofibroblasts in Human Liver Fibrosis Independent of Its Receptors , 2015 .

[35]  S. Friedman,et al.  HEPATIC FIBROSIS : Pathogenesis and Principles of Therapy , 2011 .

[36]  David Padua,et al.  Roles of TGFβ in metastasis , 2009, Cell Research.

[37]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[38]  S. Friedman,et al.  Liver fibrosis -- from bench to bedside. , 2003, Journal of hepatology.

[39]  G. Boivin,et al.  TGF β 2 knockout mice have multiple developmental defects that are non-overlapping with other TGF β knockout phenotypes , 1997 .